Want to see HK:6821 full AI Analyst Report?
Top Page
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
(6821)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$186.00
â–²(41.98% Upside)
Action:Reiterated
Date:10/01/26
The score is driven primarily by resilient financial positioning (very low leverage and strong equity base) and strong recent revenue momentum, supported by a clear upward technical trend. These positives are offset by weaker cash conversion (TTM free cash flow slightly negative) and a demanding valuation (P/E 65 with a low dividend yield).
Positive Factors
Integrated CDMO service model
The integrated CDMO model lets Asymchem support customers from development through commercialization, broadening its role in drug programs and creating opportunities for repeat work. Exposure to both R&D services and GMP manufacturing can support customer continuity as successful compounds advance.
Negative Factors
Sustained margin deterioration
The decline in gross and net margins shows that recent revenue growth is producing less profit than during the 2022–2023 peak. Persistent margin pressure could limit earnings conversion, reduce the benefit of scale, and constrain internally funded investment despite strong top-line momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated CDMO service model
The integrated CDMO model lets Asymchem support customers from development through commercialization, broadening its role in drug programs and creating opportunities for repeat work. Exposure to both R&D services and GMP manufacturing can support customer continuity as successful compounds advance.
Read all positive factors
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$78.24B
Dividend Yield0.9%
Average Volume (3M)963.13K
Price to Earnings (P/E)65.0
Beta (1Y)0.99
Revenue Growth16.62%
EPS Growth>-0.01%
CountryHK
Employees10,617
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.90
Shares Outstanding27,834,510
10 Day Avg. Volume548,300
30 Day Avg. Volume963,131
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$147.32Price Target Upside12.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.37
Revenue Forecast (FY)HK$9.42B
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, developm...
How the Company Makes Money
Asymchem Laboratories (Tianjin) Co., Ltd. makes money by charging pharmaceutical and biotech customers for outsourced chemistry development and manufacturing services. Key revenue streams typically include: (1) Process development and CMC services...
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
53
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.05B | 6.67B | 5.80B | 7.83B | 10.26B | 4.64B |
| Gross Profit | 2.86B | 2.80B | 2.46B | 4.00B | 4.86B | 2.06B |
| EBITDA | 1.43B | 1.85B | 1.58B | 3.03B | 4.08B | 1.41B |
| Net Income | 1.03B | 1.13B | 948.95M | 2.27B | 3.30B | 1.07B |
Balance Sheet | ||||||
| Total Assets | 20.83B | 20.28B | 19.29B | 19.77B | 18.24B | 15.16B |
| Cash, Cash Equivalents and Short-Term Investments | 6.61B | 7.44B | 7.33B | 9.02B | 7.44B | 6.64B |
| Total Debt | 514.12M | 256.47M | 282.53M | 118.71M | 138.35M | 434.49M |
| Total Liabilities | 3.09B | 2.63B | 2.43B | 2.26B | 2.54B | 2.55B |
| Stockholders Equity | 17.74B | 17.64B | 16.85B | 17.48B | 15.65B | 12.61B |
Cash Flow | ||||||
| Free Cash Flow | -63.29M | 137.22M | 124.33M | 2.31B | 1.14B | -1.55B |
| Operating Cash Flow | 1.59B | 1.41B | 1.25B | 3.55B | 3.29B | 113.15M |
| Investing Cash Flow | -1.87B | -633.20M | -1.18B | -2.69B | -4.67B | -2.21B |
| Financing Cash Flow | -501.93M | -344.83M | -1.93B | -542.03M | -742.53M | 6.21B |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Technical Analysis
Positive
131.00
Price Trends
136.52
Positive
120.21
Positive
102.52
Positive
Market Momentum
9.01
Negative
61.32
Neutral
82.29
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6821, the sentiment is Positive. The current price of 131 is below the 20-day moving average (MA) of 157.32, below the 50-day MA of 136.52, and above the 200-day MA of 102.52, indicating a bullish trend. The MACD of 9.01 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 82.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6821.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$238.34B | 40.01 | 10.51% | ― | 21.93% | 21.94% | |
69 Neutral | HK$111.66B | -18.31 | -16.23% | 0.35% | 53.48% | -120.02% | |
68 Neutral | HK$78.24B | 65.04 | 5.86% | 0.90% | 16.62% | >-0.01% | |
63 Neutral | HK$3.79B | 17.58 | 4.45% | 0.27% | 7.38% | 7.90% | |
59 Neutral | HK$88.41B | 46.36 | 10.96% | 0.71% | 20.39% | 26.48% | |
58 Neutral | HK$2.35B | 28.18 | 3.02% | ― | 10.32% | 178.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
165.50
68.35
70.35%
HK:1548
Genscript Biotech
42.90
25.24
142.92%
HK:2269
Wuxi Biologics (Cayman)
56.70
14.70
35.00%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
32.16
4.43
15.99%
HK:1521
Frontage Holdings Corp.
1.15
-0.15
-11.54%
HK:1873
Viva Biotech Holdings
1.69
-1.58
-48.32%
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Corporate Events
Asymchem Moves to Update Articles After Capital Increase from A Share Incentive Plan
Sep 28, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. plans to amend its articles of association to reflect an increase in registered capital following the issuance and allotment of new A shares under its 2026 A Share Restricted Share Incentive Scheme. The re...
Asymchem Calls October 2026 EGM to Amend Articles of Association
Sep 28, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has called its fourth extraordinary general meeting of 2026 for 20 October in Tianjin, asking shareholders to vote on a special resolution to amend its Articles of Association. Only H shareholders on the r...
Asymchem launches 2026 H share incentive grants for executives and staff
Sep 1, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has granted a total of 3,879,500 H share awards under its 2026 H Share Scheme, allocating 2,144,000 shares to connected persons including four directors and senior executives, and 1,735,500 shares to other...
Asymchem Grants Majority of 2026 A Scheme Restricted Shares to Key Staff
Aug 25, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has launched the initial round of grants under its 2026 A Share Scheme, awarding 2,711,000 restricted A shares to 622 incentive participants, mainly key technology and business staff and senior managers ac...
Asymchem Posts Double-Digit Revenue Growth but Lower Interim Net Profit
Aug 24, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed PRC-based provider of contract development and manufacturing services to pharmaceutical and life sciences clients, reported its unaudited interim financial results for the six months en...
Asymchem Laboratories Reports Strong Turnout and Regulated Voting at 2026 Extraordinary Meeting
Aug 20, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported the poll results of its third extraordinary general meeting of 2026, held on 20 August in Tianjin as an on-site meeting with parallel online voting for A shareholders via Shenzhen Stock Exchange s...
Asymchem Completes Small Share Repurchase Under 2025 Incentive Scheme
Aug 19, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has completed the repurchase and cancellation of 117,500 Restricted A Shares originally granted under its 2025 A Share restricted share incentive scheme to former employees who have resigned. Following the...
Asymchem Labs Sets Board Meeting to Approve 2026 Interim Results
Aug 12, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed Chinese pharmaceutical services group, operates through multiple subsidiaries to deliver laboratory-based support for drug development and related biotech activities across various mark...
Asymchem Calls 2026 EGM to Approve New Share Schemes and Biotech Investment
Jul 31, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a PRC-incorporated joint stock company with H shares listed in Hong Kong, operates in the pharmaceutical and biotechnology services sector, including activities through Shanghai Asymchem Biotechnology Dev...
Asymchem Plans 2026 H Share Restricted Scheme to Align Incentives
Jul 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has proposed the adoption of a new 2026 H Share Restricted Share Scheme to strengthen its long-term incentive framework for directors, senior management and employees. The plan, which involves issuing or a...
Asymchem Injects RMB1.24 Billion Into CDMO Subsidiary in Connected Deal
Jul 30, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a China-based CDMO services provider, is boosting the capital base of its non-wholly owned subsidiary Shanghai Asymchem Biotechnology Development. The move fits its broader strategy of using external inve...
Asymchem Laboratories Reports Strong Turnout at 2026 Extraordinary and Class Meetings
Jul 10, 2026
Asymchem Laboratories held its second extraordinary general meeting of 2026 alongside separate class meetings for its A shares and H shares in Tianjin on 10 July, with voting conducted both on site and online via Shenzhen Stock Exchange systems. T...
Asymchem Clarifies Size of H-Share Restricted Share Grant
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed Chinese pharmaceutical services company, is overseen by a board chaired by CEO Dr. Hao Hong and composed of executive, non-executive and independent non-executive directors. The company...
Asymchem Expands H Share Incentive Grants Without Diluting Shareholders
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has made a further grant of H share awards under its Restricted Share Scheme, allocating a total of 640,000 incentive H shares to executive directors and other employees. The grants, priced at RMB1.00 per ...
Asymchem Proposes 2026 A Share Incentive Scheme for Key Staff
Jul 8, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a PRC-based joint stock company listed in Hong Kong, operates in the pharmaceutical and biotechnology services industry with a focus on research, development and manufacturing support. Its operations rely...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.